Search clinical trials for: nimotuzumab plus paclitaxel

Total 8865 results

Biotech Pharmaceutical Co., Ltd.

Not yet recruiting

Nimotuzumab Combined With Paclitaxel for Recurrent Metastatic Gastric or Esophagogastric Junction Adenocarcinoma (NOTABLE-307)

Gastric or Esophagogastric Junction Adenocarcinoma
Sun Yat-sen University

Recruiting

Radiotherapy Plus Nimotuzumab or Cisplatin in Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Peking Union Medical College Hospital

Not yet recruiting

Nimotuzumab Plus Tislelizumab for Recurrent and Metastatic Cervical Cancer

Cervical Cancer
Zhejiang Cancer Hospital

Unknown

Study of Nimotuzumab in Combination With Neoadjuvant Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma Resectable

China
Biotech Pharmaceutical Co., Ltd.

Unknown

Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinomas

China
Biotech Pharmaceutical Co., Ltd.

Unknown

Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer

Nasopharyngeal Cancer

China
Xijing Hospital

Not yet recruiting

Nimotuzumab Combined With Neoadjuvant Chemotherapy in the Treatment of Resectable LA HNSCC

Head and Neck Squamous Cell Carcinoma
Chinese PLA General Hospital

Unknown

Nimotuzumab Plus S1 Versus Placebo Plus S1 as Maintenance Treatment in Patients With Unresectable Pancreatic Cancer

Unresectable Pancreatic Cancer

China
Cancer Institute and Hospital, Chinese Academy...

Unknown

Combination of Nimotuzumab,Capecitabine and Radiotherapy for Inoperable or Recurrent Gastric Cancer

Gastric Cancer | Concurrent Chemoradiotherapy

China
Peking University
Biotech Pharmaceutical Co., Ltd.

Unknown

Safety and Efficacy Study of Target Therapy Combined With Radiotherapy to Treat Senile Locally Advanced SCCHN

SCCHN
Tianjin Medical University Cancer Institute and...
Biotech Pharmaceutical Co., Ltd.

Unknown

Nimotuzumab in Combination With Paclitaxel Liposome and Carboplatin (TP Regimen) for the Advanced NSCLC Patients (NSCLC)

Non-small Cell Lung Cancer

China
Peking University

Unknown

Study of Nimotuzumab to Treat Esophageal Squamous Cell Carcinoma.

Esophageal Squamous Cell Cancer

China
Oncoscience AG
Heinrich-Heine University, Duesseldorf; University of Kiel; Johann Wolfgang Goethe... and other collaborators

Completed

Nimotuzumab in Adults With Glioblastoma Multiforma

Adults With Glioblastoma Multiforma

Germany
University of Saskatchewan

Recruiting

Evaluation of 89Zr-DFO-nimotuzumab for Non-invasive Imaging of EGFR+ Cancers by Positron Emission Tomography (PET)

Colorectal Cancer | Lung Cancer

Canada
YM BioSciences
CIMYM BioSciences

Terminated

A Study of Nimotuzumab in Combination With Radiation Therapy in Patients With Brain Metastases

Metastatic Non-Small Cell Lung Cancer

United States, Korea, Republic of, Canada, Cuba, Pakistan
Oncoscience AG
Heinrich-Heine University, Duesseldorf; University of Wuerzburg; Children's Medical... and other collaborators

Completed

Nimotuzumab in Children With Intrinsic Pontine Glioma

Diffuse Instrinsic Ponitine Glioma

Germany
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma

Esophageal Cancer | Chemotherapy | Immunotherapy | Chemoradiotherapy | Nimotuzumab

China
Health Science Center of Xi'an Jiaotong University

Recruiting

Efficacy and Safety of Caldonirimab Plus Nimotuzumab for Recurrent or Metastatic Cervical Cancer (GCR-05)

Cervical Cancer

China
University of Saskatchewan
Western Economic Diversification Canada

Recruiting

Evaluation of IRDye800CW-nimotuzumab in Lung Cancer Surgery

Lung Cancer

Canada
People's Hospital of Guangxi
Wu Jieping Medical Foundation

Unknown

Preoperative Chemoradiotherapy Combined With Nimotuzumab for Cervical Cancer

Locally Advanced Cervical Cancer

China
Peking University

Unknown

mFOLFIRI Combine With Nimotuzumab Second Line Chemotherapy for Squamous-cell Carcinoma of the Esophagus

Advanced Esophageal Carcinoma

China
The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

Study of Anti-PD-1 Antibody SHR-1210 Plus Nimotuzumab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Biotech Pharmaceutical Co., Ltd.

Unknown

Phase IV Clinical Trial of Nimotuzumab in the Treatment of Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
National Institute of Cancerología
National Heart Institute, Mexico; Pisa S.A de C.V

Completed

Combination of Nimotuzumab Cisplatin-Vinorelbine in First Line Chemotherapy in Recurring-Persistent Cervical Carcinoma

Palliative Treatment | Cervical Cancer Recurrent or Persistent | Monoclonal Antibody in Cervical Cancer Treatment

Mexico
Peking University
Biotech Pharmaceutical Co., Ltd.

Unknown

Study of Nimotuzumab to Treat Colorectal Cancer

Advanced Colorectal Cancer

China
YM BioSciences
CIMYM BioSciences

Terminated

A Study of Nimotuzumab in Combination With External Radiotherapy in Non-Small Cell Lung Cancer

Non-small-cell Lung Cancer

Canada, United States, Singapore
Tianjin Medical University Cancer Institute and...

Recruiting

Evaluating Nimotuzumab in Combination With AG Regimen for Pancreatic Cancer With Liver Metastases : A Prospective, Single-Arm, Phase II Study

Pancreatic Cancer

China
Sun Yat-sen University

Active, not recruiting

Concurrent Chemoradiotherapy With Nimotuzumab for High Risk Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Biotech Pharmaceutical Co., Ltd.

Withdrawn

Nimotuzumab in Combination With Cisplatin and Docetaxel for Patients With Advanced Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Taipei Veterans General Hospital, Taiwan

Completed

Concurrent Chemoradiotherapy (CCRT) With Paclitaxel Plus Cisplatin in LA Non-small-cell Lung Cancer (NSCLC)

Non-small-cell Lung Cancer

Taiwan
Biotech Pharmaceutical Co., Ltd.

Completed

A Real-world Study of the Efficacy and Safety of Nimotuzumab in Combination With Chemoradiotherapy for LASCCHN (Redbull-1)

Locally Advanced Head and Neck Squamous Cell Carcinoma

China
Shandong Cancer Hospital and Institute

Unknown

A Phase III Study of Nimotuzumab Plus Concurrent Chemoradiotherapy in Loco-regional Esophageal Squamous Cell Carcinoma

Prosthesis Survival

China
Shengjing Hospital

Recruiting

Stereotactic Radiotherapy Combined With Adebrelimab and TCb (Nab-paclitaxel + Carboplatin) in Neoadjuvant Treatment of TNBC

Breast Cancer | Immunotherapy | Stereotactic Radiotherapy

China
Cancer Institute and Hospital, Chinese Academy...

Completed

Cisplatin and S-1 With or Without Nimotuzumab in Untreated Advanced Gastric Adenocarcinoma

Stomach Neoplasms

China
YM BioSciences
CIMYM BioSciences

Completed

Phase I Study of Nimotuzumab in Solid Tumours

Advanced and/or Metastatic Solid Tumours

Canada
Lei Li

Recruiting

Combination of Nimotuzumab and Radiotherapy for Recurrent Uterine Cervical Squamous Carcinoma

Recurrent Cervical Carcinoma | Radiotherapy | Objective Response Rate | Overall Survival | Progression-free Survival | Epidermal Growth Factor Receptor | Nimotuzumab

China
Changhai Hospital

Recruiting

Borderline Resectable Pancreatic Cancer Neoadjuvant Chemoradiotherapy Clinicaltrial-1 (BRPCNCC-1)

Pancreatic Cancer

China
El Kendi Pharmaceuticals Manufacturing Company

Completed

Evaluate Efficacy of the Association Nimotuzumab(HR3) /Cisplatin-Vinorelbine on Patients With Cervical Carcinom (CIMAHOPE)

Cervical Cancer

Algeria
Sun Yat-sen University

Recruiting

Chidamide Plus PD-1 Plus Paclitaxel of Neoadjuvant Treatment in Low HR Expression,HER2-negative Early Breast Cancer.

Breast Cancer

China
Gilead Sciences

Terminated

Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF) (RAINIER)

Idiopathic Pulmonary Fibrosis

United States, Spain, Korea, Republic of, Israel, Australia, Italy, Canada, United Kingdom, Switzerland, Germany, Poland, Czechia, Belgium, France
Sun Yat-sen University
Zhejiang Cancer Hospital; Guangxi Medical University; Wuhan University; Fujian... and other collaborators

Completed

Study of Chemotherapy Combined With Nimotuzumab in Untreated Metastatic Nasopharyngeal Carcinoma

Stage IV Nasopharyngeal Carcinoma

China
Biotech Pharmaceutical Co., Ltd.

Unknown

Nimotuzumab in Combination With Chemoradiation for Local Advanced Esophageal Squamous Cell Carcinoma

Squamous Cell Carcinoma

China
Anhui Provincial Hospital

Recruiting

Neoadjuvant Chemoradiotherapy Combined With Camrelizumab and Nimotuzumab for Esophageal Squamous Cell Carcinoma

Toxicity, Drug

China
Fudan University

Completed

Induction Chemotherapy With Nimotuzumab in Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)

Head and Neck Cancer

China
Memorial Sloan Kettering Cancer Center
Novartis Pharmaceuticals; Sai Life Sciences

Completed

BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors

Solid Tumors

United States
Biotech Pharmaceutical Co., Ltd.

Not yet recruiting

A Study of Nimotuzumab Plus Concurrent Chemoradiotherapy Sequential Maintenance Treatment for Cervical Carcinoma

Cervical Cancer
Fudan University

Completed

Anti-EGFR Therapy Plus IMRT Concurrent Chemoradiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy

Nasopharyngeal Carcinoma

China
Guiyang Medical University

Unknown

By Comparing TPF Induction Chemotherapy Combined With Nimotuzumab Concurrent Radiotherapy and Cisplatin Concurrent Radio-chemotherapy for Locally Advanced NPC

Nasopharyngeal Carcinoma

China
Air Force Military Medical University, China

Unknown

Phase II Clinical Trial of Concurrent Chemoradiotherapy Combined Nimotuzumab for Stage IIB-IVA Cervical Cancer

Cervical Cancer

China
Huazhong University of Science and Technology
CSPC Ouyi Pharmaceutical Co., Ltd.

Recruiting

Albumin-bound Paclitaxel Plus S-1 Versus SOX as First-line Treatment in Advanced or Recurrent Gastric Adenocarcinoma

Gastric Cancer

China

Search clinical trials for: nimotuzumab plus paclitaxel

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gabon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations